- Home
- ERII vs GYRE Comparison
ERII vs GYRE Comparison
Compare ERII & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERII
- GYRE
- Stock Information
- Founded
- ERII 1992
- GYRE 2002
- Country
- ERII United States
- GYRE United States
- Employees
- ERII N/A
- GYRE N/A
- Industry
- ERII Industrial Machinery/Components
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- ERII Technology
- GYRE Health Care
- Exchange
- ERII Nasdaq
- GYRE Nasdaq
- Market Cap
- ERII 762.9M
- GYRE 897.1M
- IPO Year
- ERII 2008
- GYRE N/A
- Fundamental
- Price
- ERII $14.62
- GYRE $7.54
- Analyst Decision
- ERII Buy
- GYRE Strong Buy
- Analyst Count
- ERII 4
- GYRE 1
- Target Price
- ERII $18.75
- GYRE $18.00
- AVG Volume (30 Days)
- ERII 369.5K
- GYRE 94.4K
- Earning Date
- ERII 10-29-2025
- GYRE 11-12-2025
- Dividend Yield
- ERII N/A
- GYRE N/A
- EPS Growth
- ERII 25.10
- GYRE N/A
- EPS
- ERII 0.43
- GYRE 0.02
- Revenue
- ERII $141,775,000.00
- GYRE $102,189,000.00
- Revenue This Year
- ERII $6.16
- GYRE $18.39
- Revenue Next Year
- ERII $13.06
- GYRE $48.26
- P/E Ratio
- ERII $34.28
- GYRE $457.97
- Revenue Growth
- ERII 6.19
- GYRE N/A
- 52 Week Low
- ERII $10.86
- GYRE $6.11
- 52 Week High
- ERII $20.27
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- ERII 56.27
- GYRE 46.20
- Support Level
- ERII $14.20
- GYRE $7.55
- Resistance Level
- ERII $14.65
- GYRE $8.56
- Average True Range (ATR)
- ERII 0.35
- GYRE 0.47
- MACD
- ERII -0.01
- GYRE -0.04
- Stochastic Oscillator
- ERII 67.00
- GYRE 33.77
About ERII Energy Recovery Inc.
Energy Recovery Inc is an engineering-driven technology company. It is engaged in engineering, designing, manufacturing and supplying solutions that make industrial processes more efficient and sustainable. The company operates in three segments, Water, Emerging Technologies and Corporate. It offers energy recovery devices (ERDs) and pumps as well as related products and services to the reverse osmosis desalination market. The company derives a majority of the revenue from the Water segment. Geographically, the company operates in the U.S. and other international countries.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.